Patents by Inventor Matthew Meyerson

Matthew Meyerson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT
    Publication number: 20240366620
    Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Application
    Filed: July 6, 2024
    Publication date: November 7, 2024
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILIP LIENAU, ULRIKE SACK, MARTIN LANGE
  • 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
    Publication number: 20240307362
    Abstract: Compounds of formula (I), processes for their production and their use as pharmaceuticals are described herein.
    Type: Application
    Filed: April 22, 2020
    Publication date: September 19, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Stefan Nikolaus GRADL, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN, Hassan Youssef HARB, Phi Manh DINH
  • Compounds, compositions and methods for cancer patient stratification and cancer treatment
    Patent number: 12053476
    Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: August 6, 2024
    Assignees: Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
  • Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
    Patent number: 12006555
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 11, 2024
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER
    Publication number: 20240182452
    Abstract: The present invention provides dihydropyridazinone compounds of general formula (I) in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 28, 2023
    Publication date: June 6, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Detlev SÜLZLE, Timothy LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON
  • COMPOSITIONS AND METHODS FOR MODULATING INNATE IMMUNE SIGNALING PATHWAYS
    Publication number: 20240165144
    Abstract: The present invention provides novel compositions and methods based on the discovery of the mechanisms associated with STING signaling. Compositions identified find use in treatment of diseases where STING signaling is implicated in the pathology.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 23, 2024
    Inventors: Douglas Wheeler, Matthew Meyerson
  • Covalent PPARG inverse-agonists
    Publication number: 20240150277
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 9, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
  • Covalent PPARG inverse-agonists
    Publication number: 20240109850
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 4, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Knut EIS, Elisabeth POOK, Ulf BRÜGGEMEIER, Adelaide Clara F. A. DE LEMOS, Sven CHRISTIAN, Isabel Sophie JERCHEL-FURAU, Ulrike RAUH, Nico BRÄUER, Timo STELLFELD, Anders Roland FRIBERG, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Charlotte Christine KOPITZ, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE, Timothy A. LEWIS
  • Bacterial etiology of colorectal cancer
    Patent number: 11946105
    Abstract: Methods for predicting risk of developing colorectal cancer, for treating colorectal cancer, and reducing risk of developing colorectal cancer.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 2, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Matthew Meyerson, Aleksandar Kostic
  • Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms
    Patent number: 11926874
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L1 levels.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 12, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Matthew Meyerson, Chandra Pedamallu, Sam Freeman
  • Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer
    Patent number: 11896678
    Abstract: The present disclosure provides compositions and methods for the treatment of PPARG activated cancer. For example, the present disclosure provides PPARG signaling modulators for the treatment of bladder cancer. In particular, therapeutic and/or prophylactic compositions and uses of PPARG inverse-agonists are described.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 13, 2024
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Jonathan Goldstein, Matthew Meyerson, Craig Strathdee
  • Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
    Patent number: 11873486
    Abstract: The present invention relates, in part, to methods of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an agent that inhibits or promotes the copy number, the expression level, and/or the activity of one or more biomarkers listed in Table 1 or a fragment thereof. Also provided herein are methods of detecting ADAR1 or ISG15 dependency in a high proliferation cell (e.g., a cancer cell). Also provided are methods of detected increased interferon signaling pathway activity in a high proliferation cell (e.g., a cancer cell). Included herein are methods of treating cancer with inhibitors of ADAR1 or ISG15. Methods of screening for such inhibitors are also provided herein. Methods of identifying the likelihood of a cancer to be responsive to an ADAR1 inhibitor are also provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: January 16, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Matthew Meyerson, William N. Haining, Jeffrey Ishizuka, Robert Manguso, Hugh Gannon
  • N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230416249
    Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 28, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Ulrich KLAR, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA
    Publication number: 20230405015
    Abstract: The present invention provides a method of treatment of sarcoma comprising administering to a patient in need thereof a compound of general formula (I), in which R1, R2, R3, and R4, are as defined herein, alone or in pharmaceutical compositions or combinations comprising said compounds as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 31, 2023
    Publication date: December 21, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Martin LANGE, Stefan KAULFUSS, Charlotte Christine KOPITZ, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON
  • Dihydrooxadiazinones
    Patent number: 11773070
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: October 3, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230064983
    Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 2, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • DIHYDROOXADIAZINONES
    Publication number: 20230017200
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 19, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • DIHYDROOXADIAZINONES
    Publication number: 20220396554
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 14, 2022
    Publication date: December 15, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES
    Publication number: 20220378762
    Abstract: Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.
    Type: Application
    Filed: April 22, 2020
    Publication date: December 1, 2022
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Franziska SIEGEL, Daniel KORR, Jens SCHRÖDER, Stephan SIEGEL, Heidi GREULICH, Bethany KAPLAN, Matthew MEYERSON
  • METHODS OF HIGH-THROUGHPUT IDENTIFICATION OF T CELL EPITOPES BY CAPTURING CYTOKINES ON THE SURFACE OF ANTIGEN-PRESENTING CELLS
    Publication number: 20220364079
    Abstract: The present invention relates to a methods for high throughput screening of epitopes that are involved in T cell activation.
    Type: Application
    Filed: September 23, 2020
    Publication date: November 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Matthew Meyerson, Mark N. Lee